摘要
目的探讨奥拉西坦对急性脑出血患者同型半胱氨酸(Hcy)、超敏C-反应蛋白(hs-CRP)、尿酸(UA)、半胱氨酸蛋白酶抑制剂(Cys C)及血脂指标水平的影响。方法急性脑出血患者98例依据随机数字表法随机分为观察组49例与对照组49例。对照组采用常规治疗,观察组在对照组基础上结合奥拉西坦治疗。2组疗程均为2周。结果观察组治疗后NIHSS评分低于对照组,GCS评分和ADL评分高于对照组(P<0.05);观察组血清Hcy、hs-CRP、Cys C水平治疗后低于对照组,而UA水平高于对照组(P<0.05);观察组TG、TC、LDL-C水平治疗后低于对照组(P<0.05);2组均未见严重不良反应。结论奥拉西坦可通过降低急性脑出血患者Hcy、hs-CRP、Cys C水平,增加UA水平,及改善血脂异常发挥作用,从而改善患者症状。
Objective To investigate the effect of oxiracetam on( Hcy),high sensitive C- reactive protein( hs-CRP),uric acid( UA) and cysteine protease inhibitor( Cys C) and blood lipid index level in patients with acute cerebral hemorrhage. Methods 98 patients with acute cerebral hemorrhage were randomly divided into observation group( n = 49) and control group( n = 49). The control group was given routine treatment,the observation group was given oxiracetam treatment on the basis of control group. Two groups were treated for 2 weeks. Results The observation group after treatment NIHSS score lower than control group( P〈0. 05),GCS score and ADL score higher than control group( P〈0. 05); The serum levels of Hcy,hs-CRP,Cys,C levels lower than control group post-treatment,while the level of UA was higher than that of control group( P〈0. 05); The observation group TG, TC, LDL-C levels were lower than control group post- treatment( P〈0. 05); Two groups had no severe adverse reactions.Conclusion Oxiracetam by reducing and Hcy in patients with acute cerebral hemorrhage hs-CRP,Cys C level,increased UA level,and improve blood lipid function,and thus improve symptoms.
出处
《中国生化药物杂志》
CAS
2016年第4期66-68,共3页
Chinese Journal of Biochemical Pharmaceutics